

About Biolidics Limited

Incorporated in 2009, **Biolidics** is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

Biolidics' ClearCell® FX1 System allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

Biolidics' quality assurance capabilities have been recognized through its ISO certification. Europe: CE-marked. North-America: The ClearCell® FX1 System is registered with the US FDA Class 1 medical device. The ClearCell® FX1 Run Kits are for "Research Use Only" – not for use in diagnostic procedures.

Ordering Information

Biolidics Limited

📍 81 Science Park Drive #02-03, The Chadwick
Singapore Science Park 1, Singapore 118257
☎ +65 6482 0668 ✉ sales@biolidics.com
🌐 www.biolidics.com



Biolidics is an ISO 13485 certified company
ClearCell and CTChip are registered trademark of Biolidics Limited
© 2019 Biolidics Limited. All right reserved.

Disclaimer

All warranties, both expressed and implied, with respect to the product, including but not limited to, any implied warranty or merchant ability, or fitness for a particular purpose, and all such representatives are hereby excluded to the fullest extent permitted by law. Biolidics Limited and its affiliates shall not be liable for any direct, indirect, incidental or consequential damages caused by the product. No person has any authority to bind the Company or its affiliates to any representation or warranty with respect to the product. If any part or term of this disclaimer is held to be illegal, unenforceable or in conflict with applicable law by a court of competent jurisdiction, the validity of the remaining portions of this disclaimer shall not be affected, and all rights and obligations shall be construed and enforced, as if this disclaimer did not contain the particular part or term held to be invalid. Please contact the company for more information.



Choose Live Tolerate No Labels ClearCell® FX1 System

Enrichment Solution for Circulating Tumour Cells

Bringing Clarity to Cancer


Technology

Liquid Biopsy is a **simple and minimally invasive** alternative to surgical biopsies which enables doctors to obtain more information about the disease with a simple blood draw. The information obtained from the blood draw including circulating tumors cells can provide valuable information for cancer patient disease management. It enables the understanding of cancer heterogeneity in a patient, providing more holistic information about the disease.

The ClearCell® FX1 System, a **fully automated** cell enrichment medical device for cell retrieval that can separate and enrich **wholly intact and viable** Circulating Tumour Cells, or CTCs from whole blood. This results in high consistent recovery.



Workflow



Downstream Applications

The potential downstream applications of the CTCs enriched using ClearCell® FX1 System include the following:




Cell culture

Experimental therapeutics



Genomics

DNA/RNA genetic analysis



Cytogenetics

Detection of genetic anomaly by FISH

Cytopathology

Cellular examination of microscope level



Immunofluorescence

Characterisation by IF



Principle :

The ClearCell® FX1 System is driven by CTChip® FR which enrich CTCs based on size and deformability.

Through the process of Dean Flow Fractionation (DFF), cell relocate and distribute themselves within the channel of the CTChip® FR1. The formation of the Dean vortex flows present in the biochip results in larger cells to be located along the inner wall and the smaller cells along the outer wall. The enrichment process is completed by siphoning the large cell stream into our collection outlet as the enriched circulating tumor cell fraction.

Therefore the ClearCell FX1 offers a high purity, continuous separation solution for CTC enrichment.

